Investment Thesis
vTv Therapeutics displays severely compromised operational fundamentals with a -100% YoY revenue collapse, indicating loss of primary business or divestiture of core assets. Net income appears driven by non-recurring gains rather than sustainable operations, but an exceptionally strong balance sheet ($98.1M cash, 0.01x debt-to-equity) provides substantial downside protection and runway for turnaround attempts.
Strengths
- Fortress balance sheet with $98.1M cash reserves and minimal $8.9M liabilities
- Debt-free capital structure (0.01x debt-to-equity) with exceptional liquidity (14.36x current ratio)
- Positive operating and free cash flow of $9.2M despite revenue collapse suggests underlying asset value
Risks
- Catastrophic -100% YoY revenue decline reflects complete loss of primary business or product commercialization failure
- Reported profitability metrics are artificially inflated by non-recurring items; sustainable operating income is unclear
- Pharmaceutical sector with zero operational revenue suggests either shell status post-acquisition/divestiture or failed pipeline strategy
Key Metrics to Watch
- Revenue trajectory and new product/asset acquisition announcements indicating turnaround strategy
- Operating cash flow sustainability and cash burn rate relative to $98.1M cash runway
- Breakdown of net income components to isolate recurring operational profitability from one-time gains
Financial Metrics
Revenue
36.8M
Net Income
24.1M
EPS (Diluted)
$0.00
Free Cash Flow
9.2M
Total Assets
98.8M
Cash
98.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
63.1%
Net Margin
65.5%
ROE
26.8%
ROA
24.4%
FCF Margin
24.8%
Balance Sheet & Liquidity
Current Ratio
14.36x
Quick Ratio
14.36x
Debt/Equity
0.01x
Debt/Assets
9.0%
Interest Coverage
1,789.46x
Long-term Debt
1.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:39:43.289380 |
Data as of: 2026-03-31 |
Powered by Claude AI